ArticleFrontiers in oncology2022

RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients.

Haibo Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.